ClinicalTrials.gg
CompletedNCT00309361Updated Nov 17, 2006

Study of NV-101 for Efficacy, Pharmacodynamics, and Safety in Dental Patients Undergoing Mandibular Procedures

A Phase 3 interventional study of Phentolamine Mesylate (NV-101) in Anesthesia, Dental, sponsored by Novalar Pharmaceuticals, Inc.. Completed at 1 site in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2006-11-17.

Sponsored by Novalar Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies in Hypesthesia with a site in United States — 2 open to participants now, 2 under way, none of them phase 3. Hypesthesia · United States.

Enrollment
Largest of 18
240 · median 72
Started
2006
with 2 others
Phase 3
2 of 20
none open now
Registered
2nd of 20
by date
Lead sponsor
4 of 20
Novalar Pharmaceuticals, Inc.

Among the 20 studies in Hypesthesia with a site in United States, this one has the largest enrollment of the 18 interventional ones that give a count, is one of 3 that started in 2006, is one of 2 in phase 3, and was the 2nd registered.

Hypesthesia

47 studies on the registry are indexed under Hypesthesia; 12 are open to participants now.

Browse Hypesthesia studies →

Open to participants now

2 of the 20 studies in Hypesthesia with a site in United States are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 9 Hypesthesia studies recruiting now, 7 set no upper age limit and 1 stops at 75 or younger; none take children under 18; 2 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Hypesthesia with a site in United States, or all of them as a file.
02

Study summary

This Phase 3 study is designed as a multicenter, randomized, blinded, controlled study to evaluate the efficacy, pharmacodynamics, and safety of NV-101 administered as a submucosal injection following completion of a restorative or periodontal maintenance procedure requiring local anesthesia with an agent containing a vasoconstrictor. Local vasodilation that results in more rapid clearance of the anesthetic is the proposed mechanism of action.

03

Conditions studied

  • Anesthesia, Dental

Browse trials for

Keywords

  • Soft Tissue Anesthesia (Numbness)
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female greater than or equal to 12 years
  • Sufficiently healthy, as determined by the Investigator, to receive routine dental care
  • Requires a restorative procedure in the mandible such as cavity preparation, restoration/filling, or crown or a periodontal maintenance procedure, such as teeth cleaning (non-surgical scaling and/or root planing) on the same side of the lower mouth
  • Requires one or two cartridges of local anesthesia administered by one of the following intraoral injection techniques:

    • inferior alveolar nerve block;
    • Gow-Gates nerve block;
    • Vazirani-Akinosi block;
    • mental-incisive block; or
    • supraperiosteal injection.
  • Dental procedure is completed within 60 minutes of the first administration of local anesthetic
  • Normal lower lip and tongue sensations at baseline prior to administration of local anesthetic
  • Lower lip on the side of the procedure is numb (no feeling) at the completion of the dental procedure
  • Soft tissue anesthesia recovery score of zero prior to anesthetic
  • Functional Assessment Battery by subject and observer rating is normal prior to anesthetic
  • Negative urine pregnancy test at screening in all females of past menarche (includes all females except for those whose menstrual periods have not occured for greater than or equal to 1 year after menopause, who are surgically sterilized or who had a hysterectomy)
  • Understands and gives written
  • Subjects 12 to 17 years of age give written assent and parent(s) or legal guardian(s) give written informed consent
  • Can communicate with the Investigator and study staff, and can understand and comply with the requirements of the protocol

Exclusion criteria

Exclusion Criteria:

  • History or presence of any condition that contraindicates routine dental care
  • Requires more than two cartridges of local anesthetic (excluding supplemental injections) or use of nitrous oxide or sedatives to perform the scheduled dental procedure
  • Scheduled dental procedure takes greater than 60 minutes to complete
  • Unable to tolerate 1 liter of water over 5 hours
  • Concurrent conditions: any incapacitating medical condition (e.g. unstable angina, uncontrolled cardiac arrhythmias, uncontrolled hypertension, uncontrolled hyperthyroidism); significant infection or inflammatory process of the oral cavity.
  • Concomitant medications: use of an opioid or opioid-like analgesic (e.g. codeine, tramadol, pentazocine) within 24 hours prior to administration of anesthetic
  • Allergy or intolerance to lidocaine, articaine, prilocaine, mepivacaine, epinephrine, levonordefrin, sulfites, phentolamine, or topical benzocaine
  • Has used an drug and/or participated in any clinical study within 30 days of study drug administration
  • Has participated in this study or any previous study of phentolamine mesylate for reversal of local soft tissue anesthesia (STA)
  • Any condition which, in the opinion of the Investigator, increases the risk to the subject of participating in this study or decreases the likelihood of compliance with the protocol
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Single
Enrollment
240 participants
06

What researchers measure

Primary outcomes

  1. to determine if NV-101 accelerates time to normal sensation of the lower lip compared to control, as measured by standardized palpation procedure

Secondary outcomes

  1. to determine if NV-101 accelerates the time to STAR-7 score of zero, as measured by soft tissue anesthesia questionnaire

  2. to determine if NV-101 accelerates the time to normal function, as measured by a functional assessment battery

  3. to determine if NV-101 accelerates the time to normal sensation of the tongue, as measured by standardized palpation procedure

  4. to characterize the pharmacodynamic profile of NV-101, as measured by onset and offset of treatment effect

  5. to evaluate the safety and tolerability of NV-101

07

Study locations

1 site
  • Tufts School of Dental Medicine
    Boston, Massachusetts 02111, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2006 and a completion of Jul 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2006
First posted
Mar 31, 2006
Start
Feb 2006
Completion
Jul 2006
Last update
Nov 17, 2006
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
No changes since tracking began. The registry record was last updated on Nov 17, 2006, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00309361
Lead sponsor
Novalar Pharmaceuticals, Inc.
First posted
Mar 31, 2006
Start date
Feb 2006
Completion
Jul 2006
Last update
Nov 17, 2006

Study contacts

Athena Papas, DMD
principal investigator · Tufts University
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2006. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Phentolamine

Start the discussion